跳至主要内容
临床试验/JPRN-UMIN000032849
JPRN-UMIN000032849招募中未知

Multicenter phase I/II study of switching therapy from lenalidomide and dexamethasone to elotuzumab plus lenalidomide and dexamethasone for multiple myeloma patients not achieving deep response - Switching study from Rd to ERd for multiple myeloma (EAO-18 study)

orth Japan Hematology Study Group0 个研究点目标入组 27 人开始时间: 2018年6月8日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
27

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.Patients with HIV-antibody positive 2.Patients with synchronous or metachronous malignancy except carcinoma in situ or cancer confined to the mucosa and curatively treated by local resection 3.Patients with active infectious disease 4.Pregnant women, women who could be pregnant or women who is breast feeding 5.Patients with history of hypersensitivity for the component of elotuzumab 6.Patients with other inadequate conditions determined by investigators

研究者

发起方
orth Japan Hematology Study Group

相似试验